Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05766514
Title	Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	University of Florida
Indications	myelodysplastic syndrome acute myeloid leukemia
Therapies	Cladribine + Cytarabine + Decitabine Decitabine + Venetoclax Azacitidine + Venetoclax
Age Groups:	adult \| senior
Covered Countries	USA